CoChat

Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization

Colao, Annamaria, Di Somma, Carolina, Loche, Sandro, Di Sarno, Antonella, Klain, Michele, Pivonello, Rosario, Pietrosante, Marco, Salvatore, Marco, Lombardi, Gaetano · 2000 · Clinical Endocrinology
Cited by 101

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the effect of hyperprolactinaemia and its treatment with dopamine‐agonists on bone mass and turnover in adolescent patients compared to adults. PATIENTS: Forty patients with hyperprolactinaemia (20 with disease onset during adolescence and 20 during adulthood) and 40 healthy control subjects. DESIGN: Open transverse (in patients and controls) and open longitudinal (in the patients). MEASUREMENTS: Bone mineral density (BMD) at lumbar spine and femoral neck, serum osteocalcin (OC) and urinary cross‐linked N‐telopeptides of type‐1 collagen (Ntx) levels were evaluated in patients and controls. In the 40 patients, bone mass and turnover were re‐evaluated after 12 and 24 months of treatment with bromocriptine (BRC, dose 2.5–10 mg daily), quinagolide (CV, dose 0.075–0.3 mg daily) or cabergoline (CAB, dose 0.5–1.5 mg weekly). RESULTS: Transverse study: BMD values were significantly lower in hyperprolactinaemic patients than in controls, both at lumbar spine (0.81 ± 0.01 vs. 1.010 ± 0.01 g/cm 2; P < 0.001) and femoral neck (0.71 ± 0.01 vs. 0.873 ± 0.03 g/cm 2; P < 0.001). Thirty‐two patients (80%) had osteoporosis and/or osteopenia at one or both skeletal sites. A significant inverse correlation was found between T score values measured at lumbar spine and femoral neck and the estimated disease duration. BMD was significantly lower in young than adult patients both at lumbar spine (T score, −2.4 ± 0.1 vs. −1.4 ± 0.3, P < 0.01) and at femoral neck (T score, −2.1 ± 0.05 vs. −1.5 ± 0.2, P < 0.05). Similarly, serum OC levels were significantly lower (2.0 ± 0.11 vs. 9.1 ± 2.4 μg/l, P < 0.01) while Ntx levels were significantly higher in patients than in controls (129.2 ± 1.7 vs. 80.7 ± 2.9 nmol Bone collagen equivalent (BCE)/mmol creatinine; P < 0.001). A significant inverse correlation was found between prolactin (PRL) levels and OC levels, lumbar and femoral T score values, as well as between disease duration and OC levels, lumbar and femoral T score values. A significant direct correlation was also found between Ntx levels and PRL levels and disease duration. Longitudinal study: Normalization of serum PRL levels was obtained in all patients after 6–12 months of treatment. A significant increase of serum OC levels together with a significant decrease of Ntx levels was observed after 12 and 24 months of treatment (P < 0.01). Urinary and serum calcium, phosphorus, creatinine, and serum alkaline phosphatase and parathyroid hormone levels did not change during the study period in all patients. After 12 months of therapy OC and Ntx concentrations were restored to normal. A slight but not significant increase of BMD values was recorded after 12 and 24 months of treatment. After 12 months of treatment the percent increment of BMD values in the whole group of patients was 1.13 ± 0.6% at lumbar spine and 1.2 ± 0.4% at femoral neck level, whereas after 24 months, it was 2.8 ± 0.7% at lumbar spine and 3.5 ± 0.7% at femoral neck level. After 12 months of treatment, the percent increment of BMD values was 0.7 ± 0.2% and 1.6 ± 1.1% at lumbar spine and 0.9 ± 0.5% and 1.6 ± 0.5% at femoral neck level in the young and adult patients, respectively, whereas after 24 months, it was 2.1 ± 0.8% and 3.4 ± 1.3% at lumbar spine and 2.6 ± 0.8% and 4.4 ± 1.0% at femoral neck level in the young and adult patients, respectively. CONCLUSIONS: Adolescents with prolactinoma have osteopenia or osteoporosis, a finding that strengthens the need for a prompt diagnosis. Since normalization of PRL concentrations by dopamine agonist therapy is unable to restore the bone mass, other therapeutic approaches should be considered in order to prevent further long‐term problems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.2000.00902.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 101

Metadata

Authors
Colao, A., Di Somma, C., Loche, S., Di Sarno, A., Klain, M., Pivonello, R., Pietrosante, M., Salvatore, M., & Lombardi, G.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2000-03
Volume
52
Issue
3
Pages
319-327
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2112509333
Cited by
101
References
6
FWCI
3.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. https://app.cochat.ai/papers/10.1046/j.1365-2265.2000.00902.x
The paper
Colao, A., Di Somma, C., Loche, S., Di Sarno, A., Klain, M., Pivonello, R., Pietrosante, M., Salvatore, M., & Lombardi, G. (2000). Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2000.00902.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.